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1. Introduction
Many factors, both clinical and physical, need careful
consideration in order to select the optimal activity
of yttrium-90 (90Y) resin microspheres for a speciﬁc
patient.
First, it is helpful for non-radiation oncologists and
non-nuclear medicine physicians to clarify some terms
to improve accuracy of communication. For example,
the term ‘dose’ is often used to describe the amount
of 90Y microspheres prescribed or delivered to a patient.
However, the proper term is ‘activity’, which is the
strength of an x-ray source. For radioactive decay, activity
of the isotope is deﬁned in SI units of Becquerel (Bq).
Thus, the number of atoms that decay per second is a Bq,
which for 90Y is 2.7×10−11 Ci. Henri Becquerel shared the
1903 Nobel Prize in medicine with Pierre and Marie Curie
for discovering radioactivity.
Dose is deﬁned as the amount of energy absorbed
in tissue, with SI units of Gray (Gy); 100 cGy equals
100 rad which equals 1Gy or 1 joule of energy absorbed
per kilogram of tissue. The transposition of activity
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and dose is a common error in reporting and other
communications involving selective internal radiation
therapy (SIRT). Further suggestions on creating more
uniform and accurate publications on SIRT are detailed
in three recent consensus guidance documents. 1−3 While
the activity of 90Y is directly measured in the delivery vial
prior to implantation into liver tumours, the absorbed
dose in implanted tissues cannot be directly measured,
and this aspect of SIRT is the subject of extensive
ongoing research. Unlike routine forms of brachytherapy
where the radiation source is visible on imaging,
the dose from 90Y cannot be accurately measured or
estimated at this time.
2. Hepatic tolerance to radiation therapy
Most literature on radiation and liver tolerance was
generated from external beam radiation therapy, which
differs fundamentally from SIRT. 4−8 External beam
radiation uses a brief (seconds) pulse of high-dose
rate (>500 cGy/minute), uniform and deeply penetrat-
ing (>10 cm) energy photons (electromagnetic energy,
no mass, no charge). By contrast, SIRT provides contin-
uous (days) low-dose rate (<50 cGy/min), short distance
(<3mm) penetration from beta particles (charge,mass). 8,9
There are, however, a number of clinical reports 1,2,8,10−14
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and human dosimetry studies 7,15,16 which focus exclu-
sively on SIRT and are a useful aid in determining the
90Y activity that should be delivered to a patient.
The most serious potential complication of SIRT,
which is related to activity selection, is radiation-
induced liver disease (RILD). This term is commonly
used to describe external beam ‘radiation hepatitis’. 4,5
RILD can be fatal and has similarities to veno-occlusive
disease pathologically. 4,5,8 It can be argued, however,
that a unique term is required to distinguish the
clinicopathological features displayed by SIRT patients
from those displayed by patients receiving external
radiation who develop liver failure or severe dysfunction
without tumour progression. Sangro and colleagues
published a detailed review of their experience with SIRT
in patients who developed some features of RILD, but also
several ﬁndings inconsistent with classic RILD. 11 Sangro
termed SIRT-related RILD-like hepatic dysfunction −
RadioEmbolization Induced Liver Disease (REILD), which
shares similar ﬁndings with chemotherapy-radiation
therapy-induced liver disease. 11 Table 1 lists the key
features of RILD and REILD as described in two detailed
reports. 6,11
Table 1 – Comparison of the features of RILD and REILD
Feature RILDa REILDb
Total bilirubin Anicteric Elevated >3mg/dL
Ascites Present Present
Rapid weight gain Present Present
Presentation 2−16 weeks 4−8 weeks
AST and ALT Normal Normal
Alkaline phosphatase Elevated Possible
Prior chemotherapy None Present
Mortality 10−20% <10%
Boldface text emphasizes key differences in clinical presentation
between RILD and REILD.
a Radiation induced liver disease. 6
b Radioembolisation induced liver disease. 11
3. Risk factors for REILD
It is important to recognise known and suspected
factors that increase the risk of SIRT-related hepatic
disease. Each patient has a different risk of serious
liver injury from SIRT, and part of the skill and art
of using SIRT is to develop a keen understanding of
the parameters, treatment history, tumour histology,
anatomic, and vascular issues that can increase the
risk of irreversibly damaging the liver with radioactive
microspheres. Sangro identiﬁed, via multivariate analy-
sis, three factors which were signiﬁcantly associated with
the development of REILD following the administration
of 90Y resin microspheres, namely: age <55 years,
activity of 90Y delivered relative to targeted liver volume
(>0.8GBq/L), and diffuse disease. 11 Similarly, Goin and
Salem identiﬁed, via multivariate analysis, the following
high-risk features in hepatocellular carcinoma patients
receiving 90Y glass microspheres: ascites, diffuse disease
(which included inﬁltrating tumor type and disease
with nodules too numerous to count on pretreatment
imaging), >70% replacement of liver by tumour, aspartate
aminotransferase or alanine aminotransferase levels
greater than ﬁve times the upper limit of normal,
and total serum bilirubin level greater than 2mg/dL
(normal range, 0−1.3mg/dL). 13,14 Kennedy reported risk
factors for REILD in mostly metastatic tumours receiving
90Y resinmicrospheres in 515 patients via 680 treatments.
Similar to other reports, liver toxicity was highly
correlated with small liver volumes receiving high
activities (GBq) of 90Y, and the use of the empiric method
of activity calculation. 8
4. Conclusions
Patient selection and activity (GBq) of 90Y microspheres
calculations are the most important decisions made by
the treatment team that effect toxicity and outcome.
Careful evaluation of liver health, functional residual
liver volume and adherence to consensus guidelines 1,12
in the activity selection for each patient will improve the
chances of success.
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